ArticleBMC chemistry2026
Development and validation of method for determination of esomeprazole and ketorolac tromethamine in combined drug by RPHPLC.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined dosages offer several advantages over single dosages, including fewer pills to take daily, simplified regimens, and enhanced therapeutic effects. Therefore, a straightforward, selective, and fast reversed-phase HPLC method has been established and validated for the simultaneous analysis of Esomeprazole and Ketorolac tromethamine in a combined dosage form. There was no interference with diluents, and the procedure was specific. The average recovery rates for Esomeprazole and Ketorolac Tromethamine are 99.96% and 99.934%, respectively. The suggested approach was accurate and precise, with the system precision having a percentage RSD of 0.09%, the assay precision a percentage RSD of 0.21%, and an intermediate precision of 0.43%. The correlation coefficient was found to be 0.998 from a linearity study, indicating that the method was linear over the range of 40%, 80%, 100%, 120%, and 160%. Under all degradation conditions, there was no interference at the retention time of the Ketorolac Tromethamine and Esomeprazole peaks, and the peak purity index met compliance. Drugs can be degraded through acid hydrolysis and oxidation; however, these processes do not affect the method. The approach was found to be resilient to potential modifications. To determine the quality of the drug substance during routine analysis with consistent and repeatable results in combined dose formulations, the proposed method is not only practical and reliable but also environmentally sustainable, making it a more effective solution for analyzing Esomeprazole and Ketorolac Tromethamine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.